Christopher Golden
Clinical & Laboratory Dermatological Immunology · Stockbridge, GANPI 1053408062
Payments from drug & device makers
Across 431 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Sun Pharmaceutical Industries Inc.$941
- Johnson & Johnson$562
- Lilly USA, LLC$559
- Incyte Corporation$524
- plus $3K from 22 others
What the payments were for
- Food & beverage$9,05498%
- Education$1672%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 91 | $2,003 |
| Regeneron Healthcare Solutions, Inc. | 39 | $1,181 |
| Sun Pharmaceutical Industries Inc. | 51 | $941 |
| Johnson & Johnson | 34 | $562 |
| Lilly USA, LLC | 26 | $559 |
| Incyte Corporation | 23 | $524 |
| Novartis | 26 | $487 |
| E.r. Squibb & Sons, L.L.C. | 22 | $466 |
| Arcutis Biotherapeutics, Inc. | 13 | $347 |
| Sanofi | 16 | $327 |
| Amgen | 13 | $320 |
| Pfizer | 17 | $297 |
| LEO Pharma Inc. | 10 | $203 |
| Almirall LLC | 7 | $142 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $129 |
| UCB, Inc. | 3 | $106 |
| Boehringer Ingelheim | 4 | $88 |
| Galderma Laboratories, L.p. | 4 | $87 |
| Mayne Pharma Commercial LLC | 6 | $78 |
| ANI Pharmaceuticals, Inc. | 3 | $76 |
| Genentech USA, Inc. | 3 | $68 |
| Fresenius Kabi USA, LLC | 3 | $50 |
| Dermavant Sciences, Inc. | 2 | $40 |
| DUSA Pharmaceuticals, Inc. | 2 | $35 |
| Taro Pharmaceuticals USA, Inc. | 2 | $35 |
| Organon | 2 | $31 |
| Verrica Pharmaceuticals Inc. | 1 | $25 |
| Botanix SB Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical & laboratory dermatological immunology providers in Georgiato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 27 | $129,860 |
| Clobetasol Propionate | 132 | $4,990 |
| Fluorouracil | 61 | $4,408 |
| Ketoconazole | 175 | $3,306 |
| Metronidazole | 34 | $3,293 |
| Fluocinonide | 32 | $1,996 |
| Imiquimod | 77 | $1,965 |
| Triamcinolone Acetonide | 165 | $1,733 |
| Fluticasone Propionate | 69 | $1,422 |
| Clindamycin Phosphate | 21 | $864 |
| Hydroxyzine Hcl | 20 | $360 |
| Doxycycline Hyclate | 14 | $328 |
| Mupirocin | 44 | $295 |
| ValacyclovirValacyclovir Hcl | 12 | $284 |
| Cephalexin | 16 | $282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $320 | $129,86027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical & laboratory dermatological immunology providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.